Warning Letter to Stanislaw R. Burzynski, M.D., Ph.D. (clinical investigator), Ref. 13-HFD-45-11-04 (2013)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Scientific Investigations · December 3, 2013

U.S. Food et al., 2013-12-03: FDA warning letter to Burzynski as clinical investigator after a 7 January-15 March 2013 inspection of protocols BT-09, BT-10, BT-21, BT-22 and AD-02, finding failures in protocol adherence and human-subject protection.

we conclude that you did not adhere to the applicable statutory requirements and FDA regulations governing the conduct of clinical investigations and the protection of human subjects

HTML letter, unpaginated

U.S. Food et al., 2013-12-03: FDA warning letter to Burzynski as clinical investigator after a 7 January-15 March 2013 inspection of protocols BT-09, BT-10, BT-21, BT-22 and AD-02, finding failures in protocol adherence and human-subject protection. Regulatory record; no funder or conflicts. The letter followed Form FDA 483 observations and Burzynski's 5 April 2013 written response plus a 15 May 2013 progress report. Original fda.gov URL (fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm378237.htm) now returns 404 after FDA's site reorganisation; the archived copy is the same document. Companion letter to the institute is CHF-16. Study type: regulatory record.